IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION

IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION

The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard...

Full description

Bibliographic Details
Main Author: Yu. M. Lopatin
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2012-08-01
Series:Российский кардиологический журнал
Subjects:
chronic heart failure
beta-blockers
if channel inhibitor ivabradine
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1238
id doaj-c56189bea4fb4211914345e7323cf632
record_format Article
spelling doaj-c56189bea4fb4211914345e7323cf6322021-07-28T14:02:17Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202012-08-01046111039IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTIONYu. M. Lopatin0Volgograd State Medical University, Volgograd Region Cardiology Centre, VolgogradThe paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management.https://russjcardiol.elpub.ru/jour/article/view/1238chronic heart failurebeta-blockersif channel inhibitor ivabradine
collection DOAJ
language Russian
format Article
sources DOAJ
author Yu. M. Lopatin
spellingShingle Yu. M. Lopatin
IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
Российский кардиологический журнал
chronic heart failure
beta-blockers
if channel inhibitor ivabradine
author_facet Yu. M. Lopatin
author_sort Yu. M. Lopatin
title IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
title_short IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
title_full IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
title_fullStr IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
title_full_unstemmed IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
title_sort if channel inhibitor ivabradine and chronic heart failure management: from discussion to action
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2012-08-01
description The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management.
topic chronic heart failure
beta-blockers
if channel inhibitor ivabradine
url https://russjcardiol.elpub.ru/jour/article/view/1238
work_keys_str_mv AT yumlopatin ifchannelinhibitorivabradineandchronicheartfailuremanagementfromdiscussiontoaction
_version_ 1721269476275519488

Similar Items